Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | Defining the role of NFIC in AML

Namrata Rastogi • 2 Apr 2019
BSH 2019
Acute Myeloid Leukemia Leukemia

Namrata Rastogi, PhD, Cardiff University, Cardiff, UK, discusses her research into nuclear factor I/C (NFIC), a transcription factor, and it’s role in acute myeloid leukemia (AML). This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Namrata Rastogi

2:48
Preclinical results of a CD200-directed antibody in AML
Namrata Rastogi • 2 Apr 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals